Expression of SLC25A48 in Chronic Obstructive Pulmonary Disease

Background:

Chronic obstructive pulmonary disease is the third leading cause of death worldwide, characterized by airflow limitation, alveolar damage, and chronic systemic inflammation. These features are closely associated with malnutrition, muscle loss, and oxidative stress. Mitochondrial dysfunction plays a critical role in immune dysregulation, with peripheral blood mononuclear cells widely used in studies on inflammation and metabolism. Choline, essential for one-carbon metabolism and immune function, requires specific transporters to enter mitochondria. SLC25A48, a newly identified mitochondrial choline transporter, is linked to impaired choline uptake, elevated reactive oxygen species, and metabolic imbalance. However, its role in chronic obstructive pulmonary disease remains unclear.

Study Design:

This multicenter, prospective observational study

Methods:

The expression of SLC25A48 in peripheral blood mononuclear cells will be quantified and analyzed in relation to inflammatory markers and choline metabolism indicators. All participants will undergo pulmonary function testing, nutritional and quality of life assessments, and blood biochemistry. Peripheral blood mononuclear cells will be isolated using density gradient centrifugation, followed by protein extraction and quantification via Western blot and image-based analysis.

Inclusion criteria

• pre-COPD or COPD stages I-IV as per the 2023 GOLD guidelines (case group)
• healthy individuals without chronic diseases or major medical conditions

Exclusion criteria

• diagnosed with neuromuscular diseases
• experienced respiratory disease exacerbation requiring emergency care or hospitalization in the past three months
• assessed by a physician to have severe malnutrition or a significantly low BMI
• continuously taking folic acid supplements
• willing to receive or have already received self-paid nutrition clinic services at this hospital